Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
XOM Exxon Mobil Corp
CMI Cummins Inc
OILX UBS ETRACS S&P GSCI Crude Oil Total Return Index ETN
RUN Sunrun Inc
BAC Bank of America Corp
HLT Hilton Worldwide Holdings Inc
MNMT Motivating Masses Inc
FTA.IV First Trust Large Cap Value Oppts Alpha
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Mid Cap GrowthCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Closing Price
$132.05
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
1,927,305
0

AMD stock falls 4% on in-line earnings, revenue outlook

4:23 pm ET July 30, 2019 (MarketWatch)
Print

(END) Dow Jones Newswires

July 30, 2019 16:23 ET (20:23 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.